Dyax inks $106M development deal with Japan's CMIC

Thu, 09/30/2010 - 5:34am
Mass High Tech: The Journal of New England Technology

Dyax Corp. has entered into a development and commercialization agreement worth a total of $106 million with Japanese firm CMIC Co. Ltd. to use subcutaneous DX-88 (ecallantide) to treat hereditary angioedema (HAE) and other angioedema indications in Japan.

The deal calls for CMIC to pay Cambridge-based Dyax (Nasdaq: DYAX) a $4 million up front fee and $102 million in future development and sales milestones. CMIC will take on all costs associated with development, regulatory activities and commercialization of DX-88 for all angioedema indications in Japan under the agreement. Dyax, in turn, is eligible to receive royalties of 20 percent to 24 percent on net product sales.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.